Adial Pharmaceuticals Inc., a clinical-stage biopharmaceutical company that is focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced plans to enter the genetic testing market. The announcement came after receiving a Notice of Allowance from the United States Patent and Trademark Office for using the company’s genetic diagnostic panel combined with the company’s genetic diagnostic board (AUD).
The company’s use of its genetic diagnostic panel in combination with AD04 for the treatment of Opioid Use Disorder is likewise covered by the patent covered by the Notice of Allowance (OUD). This new patent, which relates to using our genetic diagnostic panel in combination with AD04 for the treatment of AUD and OUD, is a significant step forward since we believe that genetic testing of patients can be utilized to identify individuals who would benefit from AD04.
Furthermore, it is consistent with Adial Pharmaceuticals Inc.‘s hypothesis that the presence of specific genotypes is expected to have a significant impact on whether an individual suffering from AUD or OUD would likely respond to AD04 treatment. Once issued, the recently granted patent is intended to give market exclusivity for the AD04 genetic diagnostic test, potentially generating significant profit for the company.